Form 8-K - Current report:
SEC Accession No. 0001437749-25-008832
Filing Date
2025-03-24
Accepted
2025-03-24 07:05:51
Documents
16
Period of Report
2025-03-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20250321_8k.htm   iXBRL 8-K 22629
2 EXHIBIT 99.1 ex_793112.htm EX-99.1 99607
7 a01.jpg GRAPHIC 10221
  Complete submission text file 0001437749-25-008832.txt   299496

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20250324.xsd EX-101.SCH 3579
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20250324_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20250324_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20250324_pre.xml EX-101.PRE 11584
18 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250321_8k_htm.xml XML 2845
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 25762201
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)